Literature DB >> 17384680

Prevalence and specificity of LKB1 genetic alterations in lung cancers.

S Matsumoto1, R Iwakawa, K Takahashi, T Kohno, Y Nakanishi, Y Matsuno, K Suzuki, M Nakamoto, E Shimizu, J D Minna, J Yokota.   

Abstract

Germline LKB1 mutations cause Peutz-Jeghers syndrome, a hereditary disorder that predisposes to gastrointestinal hamartomatous polyposis and several types of malignant tumors. Somatic LKB1 alterations are rare in sporadic cancers, however, a few reports showed the presence of somatic alterations in a considerable fraction of lung cancers. To determine the prevalence and the specificity of LKB1 alterations in lung cancers, we examined a large number of lung cancer cell lines and lung adenocarcinoma (AdC) specimens for the alterations. LKB1 genetic alterations were frequently detected in the cell lines (21/70, 30%), especially in non-small cell lung cancers (NSCLCs) (20/51, 39%), and were significantly more frequent in cell lines with KRAS mutations. Point mutations were detected only in AdCs and large cell carcinomas, whereas homozygous deletions were detected in all histological types of lung cancer. Among lung AdC specimens, LKB1 mutations were found in seven (8%) of 91 male smokers but in none of 64 females and/or nonsmokers, and were significantly more frequent in poorly differentiated tumors. The difference in the frequency of LKB1 alterations between cell lines and tumor specimens was likely to be owing to masking of deletions by the contamination of noncancerous cells in the tumor specimens. These results indicate that somatic LKB1 genetic alterations preferentially occur in a subset of poorly differentiated lung AdCs that appear to correlate with smoking males.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17384680      PMCID: PMC3457639          DOI: 10.1038/sj.onc.1210418

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers.

Authors:  M Sanchez-Cespedes; S A Ahrendt; S Piantadosi; R Rosell; M Monzo; L Wu; W H Westra; S C Yang; J Jen; D Sidransky
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

2.  Pathogenetic and biologic significance of TP14ARF alterations in nonsmall cell lung carcinoma.

Authors:  Myung-Jae Park; Kimihiro Shimizu; Tetsuhiro Nakano; Yong Bum Park; Takashi Kohno; Masachika Tani; Jun Yokota
Journal:  Cancer Genet Cytogenet       Date:  2003-02

3.  Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1).

Authors:  Marianne Tiainen; Kari Vaahtomeri; Antti Ylikorkala; Tomi P Mäkelä
Journal:  Hum Mol Genet       Date:  2002-06-15       Impact factor: 6.150

4.  A serine/threonine kinase gene defective in Peutz-Jeghers syndrome.

Authors:  A Hemminki; D Markie; I Tomlinson; E Avizienyte; S Roth; A Loukola; G Bignell; W Warren; M Aminoff; P Höglund; H Järvinen; P Kristo; K Pelin; M Ridanpää; R Salovaara; T Toro; W Bodmer; S Olschwang; A S Olsen; M R Stratton; A de la Chapelle; L A Aaltonen
Journal:  Nature       Date:  1998-01-08       Impact factor: 49.962

5.  Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.

Authors:  D E Jenne; H Reimann; J Nezu; W Friedel; S Loff; R Jeschke; O Müller; W Back; M Zimmer
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

6.  LKB1 protein expression in the evolution of glandular neoplasia of the lung.

Authors:  Hassan Ghaffar; Fikret Sahin; Montserrat Sanchez-Cepedes; Gloria H Su; Marianna Zahurak; David Sidransky; William H Westra
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

7.  Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.

Authors:  Montserrat Sanchez-Cespedes; Paola Parrella; Manel Esteller; Shuji Nomoto; Barry Trink; James M Engles; William H Westra; James G Herman; David Sidransky
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

Review 8.  LKB1 tumor suppressor protein: PARtaker in cell polarity.

Authors:  Annette F Baas; Linda Smit; Hans Clevers
Journal:  Trends Cell Biol       Date:  2004-06       Impact factor: 20.808

9.  Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.

Authors:  Yoshio Tomizawa; Takashi Kohno; Haruhiko Kondo; Ayaka Otsuka; Michiho Nishioka; Toshiro Niki; Tesshi Yamada; Arafumi Maeshima; Kimio Yoshimura; Ryusei Saito; John D Minna; Jun Yokota
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

10.  Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene.

Authors:  Julian Carretero; Pedro P Medina; Ruben Pio; Luis M Montuenga; Montserrat Sanchez-Cespedes
Journal:  Oncogene       Date:  2004-05-13       Impact factor: 9.867

View more
  113 in total

Review 1.  The role of LKB1 in lung cancer.

Authors:  Montse Sanchez-Cespedes
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

2.  LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.

Authors:  Wenjin Liu; Kimberly B Monahan; Adam D Pfefferle; Takeshi Shimamura; Jessica Sorrentino; Keefe T Chan; David W Roadcap; David W Ollila; Nancy E Thomas; Diego H Castrillon; C Ryan Miller; Charles M Perou; Kwok-Kin Wong; James E Bear; Norman E Sharpless
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

3.  Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.

Authors:  Julian Carretero; Takeshi Shimamura; Klarisa Rikova; Autumn L Jackson; Matthew D Wilkerson; Christa L Borgman; Matthew S Buttarazzi; Benjamin A Sanofsky; Kate L McNamara; Kathleyn A Brandstetter; Zandra E Walton; Ting-Lei Gu; Jeffrey C Silva; Katherine Crosby; Geoffrey I Shapiro; Sauveur-Michel Maira; Hongbin Ji; Diego H Castrillon; Carla F Kim; Carlos García-Echeverría; Nabeel Bardeesy; Norman E Sharpless; Neil D Hayes; William Y Kim; Jeffrey A Engelman; Kwok-Kin Wong
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

Review 4.  Genetic changes in squamous cell lung cancer: a review.

Authors:  Rebecca S Heist; Lecia V Sequist; Jeffrey A Engelman
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

Review 5.  Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

Authors:  Po Yee Yip
Journal:  Transl Lung Cancer Res       Date:  2015-04

6.  Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells.

Authors:  Imoh S Okon; Kathleen A Coughlan; Ming-Hui Zou
Journal:  J Biol Chem       Date:  2013-11-27       Impact factor: 5.157

7.  Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator.

Authors:  Prashant Trikha; Robert L Plews; Andrew Stiff; Shalini Gautam; Vincent Hsu; David Abood; Robert Wesolowski; Ian Landi; Xiaokui Mo; John Phay; Ching-Shih Chen; John Byrd; Michael Caligiuri; Susheela Tridandapani; William Carson
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

8.  Lkb1 deletion in murine B lymphocytes promotes cell death and cancer.

Authors:  George P Souroullas; Yuri Fedoriw; Louis M Staudt; Norman E Sharpless
Journal:  Exp Hematol       Date:  2017-04-21       Impact factor: 3.084

9.  AMPK and Endothelial Nitric Oxide Synthase Signaling Regulates K-Ras Plasma Membrane Interactions via Cyclic GMP-Dependent Protein Kinase 2.

Authors:  Kwang-Jin Cho; Darren E Casteel; Priyanka Prakash; Lingxiao Tan; Dharini van der Hoeven; Angela A Salim; Choel Kim; Robert J Capon; Ernest Lacey; Shane R Cunha; Alemayehu A Gorfe; John F Hancock
Journal:  Mol Cell Biol       Date:  2016-11-28       Impact factor: 4.272

Review 10.  Controlling the master-upstream regulation of the tumor suppressor LKB1.

Authors:  Lars Kullmann; Michael P Krahn
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.